Over the past several years, multiple myeloma treatment options have expanded widely for patients, resulting in significantly improved outcomes. The FDA approved around 16 new agents and 30 treatment regimens, transforming the multiple myeloma treatment paradigm for patients with newly diagnosed and relapsed/refractory multiple myeloma. Bristol Myers Squibb (BMS) and Janssen, a subsidiary of Johnson & Johnson, are the two titans dominating the multiple myeloma treatment landscape with around nine FDA-approved products for multiple myeloma in different settings. This advancement is crucial in addressing multiple myeloma recurrence, offering new and effective soluti...
